Clinical trials: Preserved Ejection Fraction
Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal)
PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF
Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL).
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal), Persistent Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- PREACTIVE (NCT07324772)
- Testing
- progressive resistance training, combined aerobic + resistance training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Incretin Therapies in Obesity-related HFpEF
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume.
- Conditions
- Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
- Trial name
- NCT07554638
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Heart Failure With Preserved Ejection Fraction (HFpEF
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency
This study will investigate whether intravenous (IV) iron improves symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency.
- Trial name
- ISLE HFpEF (NCT07643818)
- Testing
- Ferric Derisomaltose
- Where
- Jersey
- Volunteers
- 150 people
- Sponsor
- Government of Jersey
Heart Failure, Heart Failure, Diastolic
A Preliminary Study for INFORMED
Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding…
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure
- Trial name
- PRE-INFORMED (NCT05585125)
- Testing
- Beta blocker
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Weill Medical College of Cornell University
Heart Failure With Preserved Ejection Fraction
Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection Fraction
The purpose of this study is to internally validate low-field Ex-CMR as a noninvasive tool for diagnosing, phenotyping, and risk stratifying HFpEF in patients with exertional dyspnea.
- Trial name
- NCT07401771
- Testing
- Exercise Cardiovascular Magnetic Resonance
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF)
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with…
- Conditions
- Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
- Trial name
- NCT05371496
- Testing
- Semaglutide, Counselling on healthy lifestyle intervention
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
Heart Failure, Obesity
WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise
The goal of this study is to define how treatment of obesity impacts cardiometabolic performance during exercise in patients with established HFpEF or at risk for HFpEF.
- Conditions
- Heart Failure, Obesity, Weight Loss, Heart Failure With Preserved Ejection Fraction
- Trial name
- WTLOSS-EX (NCT06576050)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
This study seeks to develop improved cardiac MRI (CMR) methods to quantify epicardial adipose tissue (EAT) composition and to demonstrate the advantages of EAT composition imaging (a) in advancing the understanding of the…
- Trial name
- NCT07178145
- Testing
- GLP-1RA
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- University of Virginia
Heart Failure Preserved Ejection Fraction
Coronary Sinus Reducer For The Management Of Symptomatic Heart Failure
The purpose of this study is to evaluate the efficacy of CS Reducer implantation in patients with HFpEF and CMD on left ventricular filling pressures, specifically invasive measurement of PAWP during standardized exercise.
- Trial name
- NCT07057323
- Testing
- Coronary Sinus Reducer
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States.
- Trial name
- FIRE-HFpEF (NCT05839730)
- Testing
- Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created…
- Conditions
- Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure
- Trial name
- NCT05719714
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwestern University
HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction
Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)
Heart failure with preserved ejection fraction (HFpEF) is a common condition among older adults. It is associated with frequent hospitalizations, impaired functional capacity, reduced quality of life, and high healthcare…
- Conditions
- HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction, Readmission Rates, Exercise Training
- Trial name
- EMPOWER-HFpEF (NCT07727096)
- Testing
- Exercise-Based Cardiac Rehabilitation, Guideline-Directed Medical Therapy
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a common and serious complication of obesity and type 2 diabetes (T2D). HFpEF occurs when the heart muscle unable to relax efficiently to pump the blood around the body.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese
- Trial name
- AMEND (NCT05887271)
- Testing
- Low calorie meal replacement plan, Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, Transthoracic echocardiography
- Where
- 3 sites in United Kingdom
- Volunteers
- 66 people
- Sponsor
- University of Leicester
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- PADN-HF-PH (NCT05824923)
- Testing
- Pulmonary arterial denervation, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Pulnovo Medical (Wuxi) Co., Ltd.
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
The goal of this clinical trial is to learn which iron treatment works better for adults with congestive heart failure and low iron levels: intravenous (IV) iron given through a vein or oral (PO) iron taken by mouth.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency
- Trial name
- IRONICA (NCT07053475)
- Testing
- Ferric Carboxymaltose, Ferrous Sulfate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Syed Hamza Mufarrih
Aging, Heart Failure With Preserved Ejection Fraction
Novel Respiratory Training as Part of Palliative Care for Older Adults With Heart Failure
In a randomized controlled trial, to study the utility of inspiratory muscle training (IMT) to improve functional outcomes in adults aged ≥70 years with heart failure (HF) who have been referred to palliative care for end-stage…
- Conditions
- Aging, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Frailty
- Trial name
- RETRO (NCT06576297)
- Testing
- Inspiratory Muscle Training (IMT), Standard of Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pittsburgh
Heart Failure With Preserved Ejection Fraction
Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients
This research is being done to better understand the relationship between information collected by wearable devices and clinical measurements in people with heart failure with preserved ejection fraction (HFpEF) and others…
- Trial name
- NCT04998877
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Heart Failure With Preserved Ejection Fraction
EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)
The goal of this clinical trial is to learn if therapy with activin ligand-trap biological therapy (an investigational drug) combined with exercise training can improve exercise capacity and cognitive function in heart failure…
- Trial name
- EXAMINE-HFC (NCT07202000)
- Testing
- Activin ligand-trap biological therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure, Type 2 Diabetes Mellitus
- Trial name
- NCT07599293
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 39,614 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Preserved Ejection Fraction
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
- Trial name
- NCT07083011
- Testing
- 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic